Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000560051 | SCV000630587 | uncertain significance | Gastrointestinal stromal tumor | 2023-10-13 | criteria provided, single submitter | clinical testing | This sequence change replaces methionine, which is neutral and non-polar, with isoleucine, which is neutral and non-polar, at codon 642 of the PDGFRA protein (p.Met642Ile). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with PDGFRA-related conditions. ClinVar contains an entry for this variant (Variation ID: 459033). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt PDGFRA protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Institute of Human Genetics, |
RCV001262590 | SCV001440518 | uncertain significance | Polyps, multiple and recurrent inflammatory fibroid, gastrointestinal | 2019-01-01 | criteria provided, single submitter | clinical testing | |
Sema4, |
RCV002258945 | SCV002538556 | uncertain significance | Hereditary cancer-predisposing syndrome | 2022-01-21 | criteria provided, single submitter | curation | |
Ambry Genetics | RCV002258945 | SCV002721539 | uncertain significance | Hereditary cancer-predisposing syndrome | 2024-07-17 | criteria provided, single submitter | clinical testing | The p.M642I variant (also known as c.1926G>A), located in coding exon 13 of the PDGFRA gene, results from a G to A substitution at nucleotide position 1926. The methionine at codon 642 is replaced by isoleucine, an amino acid with highly similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |